SETD2 Inhibitors for Pancreatic Cancer Proliferation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges with suboptimal response, relapse, and resistance to therapeutic agents, necessitating the development of more effective, safe, and durable therapies for various types of cancer, including pancreatic and esophageal cancer.
Innovation Solution
Inhibiting the human histone methyltransferase SETD2 using SETD2 inhibitors, such as polypeptides, antibodies, RNA molecules, or small molecule compounds like sinefungin derivatives, to reduce cancer cell proliferation, particularly targeting the SET domain for therapeutic effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If SETD2 is inhibited to treat cancer, then cancer cell proliferation is reduced, but the therapeutic efficacy is limited by the complexity of cancer biology and resistance mechanisms
Solution Approach 1:
The patent segments the cancer treatment approach by identifying and targeting specific functional domains of SETD2 (AWS, SET, PostSET, WW, SRI) with domain-specific inhibitors. This segmentation allows for precise inhibition of SETD2's methyltransferase activity while minimizing off-target effects, thereby reducing cancer cell proliferation through a focused molecular mechanism rather than broad non-specific treatment.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of SETD2 inhibitors to optimize binding affinity and selectivity. By adjusting molecular parameters such as binding site specificity (SET domain vs. other domains) and inhibitory concentration (IC50 values ranging from nanomolar to micromolar), the therapy achieves effective cancer cell proliferation reduction while managing therapeutic complexity through controlled molecular interactions.
2Reliability
If conventional cancer treatments are used, then cancer can be treated, but suboptimal response and relapse occur
Solution Approach 1:
The patent converts the previously understood harmful role of SETD2 inhibition (which was thought to only affect tumor suppressor function) into a beneficial therapeutic strategy. By demonstrating that SETD2 inhibition specifically targets cancer cell proliferation pathways while preserving normal tissue function, the treatment achieves durable response without the relapse issues associated with conventional cytotoxic therapies.
Solution Approach 2:
The patent incorporates feedback mechanisms through the identification of specific binding sites and domains on SETD2 that can be targeted by inhibitors. The feedback loop involves monitoring cancer cell response to SETD2 inhibition and adjusting therapeutic parameters accordingly, thereby improving treatment reliability and reducing relapse while maintaining effective proliferation control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inhibition of SETD2 demonstrates a surprising therapeutic potential for treating cancer by reducing cancer cell proliferation and viability, as evidenced by CRISPR pooled screening and domain pool screening results, indicating its dependency in various cancer cell lines, including pancreatic and esophageal cancer.
Implementation Method 1
inhibiting the human histone methyltransferase, SETD2, can be used to treat cancer
Implementation Method 2
as evidenced by CRISPR pooled screening and domain pool screening results
Data Source
AI summary
The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancer, i.e., pancreatic cancer or esophageal cancer, by administering to a human subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.